Workflow fit
Where the measurement fits your review process.
The current wedge is sponsor-side: one decision (finerenone), one review window (Ohio Medicaid P&T, July 8 2026), one circulatable artifact. The surfaces below show where the underlying measurement discipline extends.
Current wedge surface
Sponsor-side review windows.
These are the workflow surfaces closest to the current proof posture. The active authorized exhibit (finerenone) demonstrates the measurement discipline. The same unit applies across these decision types.
Coverage / Formulary / P&T Review
Is the clinical evidence claim holding or shifting before the committee meets?
Claim-state reads for pending P&T docket items — detect hardening, decay, or narrowing before the meeting packet circulates. Current wedge: finerenone in albuminuric CKD ahead of Ohio Medicaid P&T (July 8, 2026).
Request Coverage ReadMedical-Affairs Evidence Triage
Which contested claims need a proactive medical response?
Claim-state mapping across a therapeutic area identifies which public-facing claims are hardening, decaying, or narrowing — so medical affairs teams can prioritize response before the field settles.
Request Evidence MapHEOR / Value Pre-Committee Read
Is the economic narrative stabilizing or fragmenting?
Pre-committee claim trajectory reads surface whether the value evidence framing is consolidating around a specific wording or breaking into competing claims before the dossier is filed.
Request HEOR ReadSafety & Pharmacovigilance Review
Does this safety signal stay isolated or become class-wide?
Claim-hardening reads track whether a safety signal in one product begins hardening around a broader class claim. Useful when platform or mechanistic overlap creates potential contagion risk.
Request Safety Signal ReadAdjacent surfaces
Capital-side — not the current wedge.
These are surfaces the system could plausibly serve, but the current proof is built on one sponsor-side review window. No capital-side field evidence has been collected and no capital-side claims are authorized.
The system could plausibly serve portfolio-level claim-movement detection ahead of consensus events, but the current wedge is sponsor-side review windows. No capital-side proof has been built.
The system could plausibly produce memo-ready claim-state reads, but the current authorized exhibit is one lane (finerenone) with gate 0.65 not yet met. Comparative analyst-read capability is not yet demonstrated.
The system could plausibly support pre-acquisition claim scrutiny on contested asset narratives, but no PE-specific field evidence has been collected. The current proof is built on a single payer-side decision window.
What this page does not say
- This page maps claim-state intelligence to workflow surfaces. It does not assert lead-time advantage or predictive lift.
- Capital-side use cases are adjacent surfaces, not the current wedge. The current wedge is sponsor-side coverage review.
- All claims about the finerenone lane are bounded by the promotion gate (0.65). See Validation for the current authorization state.
Action
Map the measurement to your specific review window.
One claim, one decision date, one bounded read. Send a disputed claim and we return the current claim-state posture.